GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellectis SA (XPAR:ALCLS) » Definitions » EBITDA Margin %

Cellectis (XPAR:ALCLS) EBITDA Margin % : -234.45% (As of Jun. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Cellectis EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Cellectis's EBITDA for the three months ended in Jun. 2024 was €-17.56 Mil. Cellectis's Revenue for the three months ended in Jun. 2024 was €7.49 Mil. Therefore, Cellectis's EBITDA margin for the quarter that ended in Jun. 2024 was -234.45%.


Cellectis EBITDA Margin % Historical Data

The historical data trend for Cellectis's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cellectis EBITDA Margin % Chart

Cellectis Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -696.06 -84.89 -258.44 -398.41 -12,275.58

Cellectis Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -13,256.36 -7,366.90 -20,064.62 259.24 -234.45

Competitive Comparison of Cellectis's EBITDA Margin %

For the Biotechnology subindustry, Cellectis's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cellectis's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cellectis's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Cellectis's EBITDA Margin % falls into.



Cellectis EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Cellectis's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-84.947/0.692
=-12,275.58 %

Cellectis's EBITDA Margin % for the quarter that ended in Jun. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Jun. 2024 )/Revenue (Q: Jun. 2024 )
=-17.558/7.489
=-234.45 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cellectis  (XPAR:ALCLS) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Cellectis EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Cellectis's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cellectis Business Description

Address
8, rue de la Croix Jarry, Paris, FRA, 75013
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.

Cellectis Headlines

No Headlines